Dublin – Ireland, 4 December 2015 – Mainstay Medical International plc (Mainstay or the Company, listed on Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, a new implantable neurostimulation system to treat disabling Chronic Low Back Pain (CLBP), today announced additional results from the ReActiv8-A Clinical Trial, an international, multi-centre, prospective, single arm trial to gather data for a submission for CE Marking for ReActiv8. The additional results are consistent with those released on 31 August, 2015 and continue to show clinically important, statistically significant and lasting improvement in pain, disability and quality of life in this clinically challenging population.
For full access, please click here.
